Underprescription of SGLT2i and GLP-1 RA: CAREPRO-T2D (Cardiorenal Protection in Type 2 Diabetes) Cross-Sectional Study.

Francisco Simões de Carvalho,Francisca de Brito Marques,Ana Elisa Lopes,Joana Lima Ferreira,Rosa Maria Príncipe

Cureus（2023）

引用 0|浏览3

暂无评分

摘要

SGLT2i and GLP-1 RA are underprescribed in T2D, with almost two-thirds of patients not being prescribed these agents despite being strongly advised by current guidelines. These findings highlight the need for specific actions to improve T2D management at primary care level.

查看译文

关键词

atherosclerotic cardiovascular disease,glp-1 receptor agonists,heart failure,sglt2 inhibitors,type 2 diabetes

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要